The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrenceReportar como inadecuado




The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Experimental and Clinical Cancer Research

, 32:9

First Online: 13 February 2013Received: 13 January 2013Accepted: 08 February 2013DOI: 10.1186-1756-9966-32-9

Cite this article as: Xiang, Y., Xiong, H., Cui, Z. et al. J Exp Clin Cancer Res 2013 32: 9. doi:10.1186-1756-9966-32-9

Abstract

BackgroundAlthough a previous meta-analysis reported no association between metabolic syndrome MetS and prostate cancer risk, a number of studies suggest that MetS may be associated with the aggressiveness and progression of prostate cancer. However, these results have been inconsistent. This systematic review and meta-analysis investigated the nature of this association.

MethodsWe systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to January 2013 using the keywords -metabolic syndrome- and -prostate cancer-. We assessed relative risks RRs of the prostate cancer, several parameters of prostate cancer aggressiveness and progression associated with MetS using 95% confidence intervals 95% CIs.

ResultsThe literature search produced 547 hits from which 19 papers were extracted for the meta-analysis. In cancer-free population with and without MetS, the combined adjusted RR 95% CI of prostate cancer risk and prostate cancer-specific mortality in longitudinal cohort studies is 0.96 0.85 ~ 1.09 and 1.12 1.02 ~ 1.23 respectively. In the prostate cancer patients with and without MetS, the combined unadjusted OR 95% CI of high grade Gleason prostate cancer is 1.44 1.20 ~ 1.72, the OR of advanced prostate cancer is 1.37 1.12 ~ 1.68 and the OR of biochemical recurrence is 2.06 1.43 ~ 2.96.

ConclusionsThe overall analyses revealed no association between MetS and prostate cancer risk, although men with MetS appear more likely to have high-grade prostate cancer and more advanced disease, were at greater risk of progression after radical prostatectomy and were more likely to suffer prostate cancer-specific death. Further primary studies with adjustment for appropriate confounders and larger, prospective, multicenter investigations are required.

KeywordsGleason score Recurrence Clinical stage Aggressiveness AbbreviationsPCaProstate cancer

MetSMetabolic syndrome

RRRelative risk

OROdd ratio

HRHazard ratio

CIsConfidence intervals.

Electronic supplementary materialThe online version of this article doi:10.1186-1756-9966-32-9 contains supplementary material, which is available to authorized users.

Yu-zhu Xiang, Hui Xiong contributed equally to this work.

Download fulltext PDF



Autor: Yu-zhu Xiang - Hui Xiong - Zi-lian Cui - Shao-bo Jiang - Qing-hua Xia - Yong Zhao - Guan-bin Li - Xun-bo Jin

Fuente: https://link.springer.com/







Documentos relacionados